Cytopathology checklist Flashcards
CYP.00125, PT Participation
“For laboratories subject to US regulations that perform gynecologic cytopathology, the laboratory and all individuals who examine gynecologic preparations participate in the CAP Gynecologic Cytology PT Program (PAP PT) or another proficiency testing program in gynecologic cytopathology approved by CMS., NOTE: This checklist requirement applies only to US laboratories and other laboratories subject to CLIA regulations. Laboratories must maintain documentation of PT performance for at least 2 years. Documentation must be kept for each individual participating in annual PT, including identification of those who are retested; documentation of remedial training; records of imposition of limitations on slide examination; and records of re-examination of slides, as required by CLIA. , Evidence of Compliance:
- Written policy describing handling of PT failures (may include retesting, remedial training, and imposition of limitations on slide examination) AND
- Records that the laboratory is enrolled and all currently employed personnel have successfully completed PT AND
- Records of retesting, remedial training and imposition of limitations, if applicable AND
- Records of notification to the PT provider and CMS for any PAP testing personnel who left employment prior to completion of annual PT”
CYP.00150, Educational Participation
“For laboratories subject to US regulations that perform gynecologic cytopathology, the laboratory participates in the educational component of the CAP Gynecologic Cytology PT Program (PAP PT) or another educational peer-comparison program in gynecologic cytopathology., NOTE: Interlaboratory comparison programs in cytopathology provide valuable educational opportunities for peer performance comparisons in both technical and diagnostic arenas. While not completely emulating cervicovaginal cytopathologic preparation and interpretation, participation in the PAP program enables a laboratory to compare its performance to benchmarks derived from a database of peer laboratories., Evidence of Compliance:
- Records such as CAP order form, purchase order AND records of completed/submitted results indicating that the laboratory is participating in the educational component of the CAP PAP PT program OR
- Records of enrollment/participation in another educational gynecologic cytopathology peer-comparison program OR
- Records for participation in a laboratory-developed program by circulating gynecologic case material with other laboratories”
CYP.00170, Educational Participation
“For laboratories not subject to US regulations, that perform gynecologic cytopathology, the laboratory participates in the educational component of the CAP PAP Education Program or another interlaboratory peer-comparison educational program in gynecologic cytopathology., NOTE: Participation in the PAP Education program enables a laboratory to compare its performance to benchmarks derived from a national database of peer laboratories. , Evidence of Compliance:
- Records such as CAP order form, purchase order AND records of completed/submitted results indicating that the laboratory is participating in the educational component of the CAP PAP PT program OR
- Records of enrollment/participation in another educational gynecologic cytopathology peer-comparison program OR
- Records for participation in a laboratory-developed program by circulating gynecologic case material with other laboratories”
CYP.00190, Educational Participation
“For laboratories that perform non-gynecologic cytopathology, the laboratory participates in an interlaboratory peer-comparison educational program in NON-GYNECOLOGIC cytopathology (e.g. CAP Interlaboratory Comparison Program in Non-Gynecologic Cytopathology NGC). , , Evidence of Compliance:
- Records such as CAP order form, purchase order AND records of completed/submitted results indicating that the laboratory is participating in the educational component of the CAP NGC program OR
- Records of enrollment/participation in another educational non-gynecologic cytopathology peer-comparison program OR
- Records for participation in a laboratory-developed program by circulating non-gynecologic case material with other laboratories”
CYP.01650, Cytopathology Exclusion
“There is a policy that lists specimens that an institution may choose to exclude from routine submission to the cytology department for examination., NOTE: This policy should be made in conjunction with the hospital administration and appropriate medical staff departments. The laboratory director should have participated in or been consulted by the medical staff in deciding which cytology specimens are to be sent to the laboratory for examination.
This checklist item is not applicable if 1) All specimens are submitted to pathology, or 2) The laboratory is not part of an institution that provides cytologic services.
(No policy is needed for fluids such as urines and CSF that do not routinely undergo cytologic examination.), “
CYP.01900, Disparity Resolution
“If significant disparities exist between histological and cytological findings, these are resolved in a confidential peer-reviewed quality management document, or in an addendum report, as appropriate., , Evidence of Compliance:
- Written procedure defining significant disparities and the process for resolving disparities in histological/cytological findings “
CYP.02100, Consultation Report Retention
“Documented records of intra- and extra-departmental consultations are maintained., NOTE: The retention requirement for reports (10 years) applies to records of consultations., Evidence of Compliance:
- Written retention policy”
CYP.03333, FNA Specimen Labeling
“If the pathologist performs FNA procedures or if laboratory personnel participate in FNA procedures, at least two patient identifiers are placed on the prepared slides and any specimen container at the time of the procedure., NOTE: All specimens must be labeled at the time of collection to provide unique identification. Each prepared slide must be labeled separately and any specimen container with collected material (e.g. fluid from aspiration) must also be labeled. , Evidence of Compliance:
- Written procedure defining FNA specimen labeling requirements at the time of collection”
CYP.03366, FNA Error Prevention
If the pathologist performs FNA procedures, there is a documented procedure to prevent errors in the identification of the patient, the site and the procedure., ,
CYP.03700, Specimen Rejection Criteria
“There are documented criteria for rejection of specimens (e.g. inadequate requisition information, unauthorized source, broken slides)., , Evidence of Compliance:
- Records of rejected specimens”
CYP.03800, Physician Notification
“There is evidence that submitting physicians are notified when unacceptable specimens are received., , Evidence of Compliance:
- Records of physician notification (e.g. follow-up correspondence, documented telephone calls or written reports)”
CYP.03850, Cytology Assessment Record
If a statement of adequacy, preliminary diagnosis, or recommendations for additional studies is provided at the time of cytology sample collection, documentation of that statement is maintained., NOTE: Documentation might include a note in the medical record or in the final report.,
CYP.03900, Reagent Labeling
All working solutions and stains are properly labeled., NOTE: Working solutions and stains must be properly labeled with the contents, and, if applicable, expiration date and/or date changed/filtered. ,
CYP.03925, Stain Assessment
“Cytology stains are assessed at least annually to ensure their proper storage and acceptable quality., NOTE: Most stains used in the cytology laboratory are not subject to outdating, so that assignment of expiration dates may have no meaning. The acceptable performance of such stains should be confirmed at least annually by technical assessment on actual case material, and as part of the evaluation of cytopathology cases. Cytology stains undergoing a daily technical quality review are exempt from an annual assessment. Where applicable, expiration dates assigned by a manufacturer must be observed., Evidence of Compliance:
- Written procedure for stain assessment AND
- Records of assessment of appropriate quality of each cytology stain in use”
CYP.04100, Staining Solutions
Staining solutions are filtered, covered when not in use and changed in accordance with a defined protocol., ,
CYP.04150, Cross-Contamination
“There are procedures to prevent cross-contamination of specimens during processing and staining., NOTE: Procedures must prevent cross-contamination between gynecologic and non-gynecologic specimens.
Also, procedures must prevent contamination among non-gynecologic cases when highly cellular specimens are processed. Methods to minimize this potential problem may include cytocentrifuge, filter, and monolayer preparations. Direct smears made from the sediment of highly cellular cases should be stained after the other cases, and the staining fluids must be changed or filtered between each of the highly cellular cases. One procedure to detect highly cellular specimens is to use a toluidine blue, or other rapid stain, on a wet preparation. One procedure to detect possible contamination is to insert a clean blank slide in each staining run and examine it for contamination., “
CYP.04300, Daily QC
There is documented evidence of daily review of the technical quality of cytologic preparations by the pathologist or supervisory-level cytotechnologist., NOTE: The technical quality of preparations should be checked daily. This includes checking all stains for predicted staining characteristics each day of use. This check should include preparations performed in the laboratory such as cytospins, cell blocks, and liquid based automated preparations.,
CYP.04700, Slide Labeling
“Slides are adequately labeled., NOTE: All slides must be labeled to provide unique identification (i.e. accession number or another unique identifier). Each prepared slide must be labeled separately., Evidence of Compliance:
- Written procedure defining labeling requirements”
CYP.04900, Cellular/Nuclear Detail
Cellular and nuclear detail are sufficient for proper interpretation., ,
CYP.05000, On-Site Slide Review
The findings from the on-site slide review were free of any issues or any significant diagnostic discrepancies as defined in the above note., ,
CYP.05257, Implementation/Verification Protocol
“There is documentation of adherence to the manufacturer’s recommended protocol(s) for implementation and verification of new instruments., NOTE: Before implementing use of new gynecologic liquid-based methods and instruments, automated preparations, and automated screening instruments, the laboratory must verify and document the functioning of the instrument in its own specific laboratory environment, including the capability of the instrument to replace existing procedure(s), if applicable. If the manufacturer does not provide verification and instrument monitoring recommendations, the laboratory must document the specific verification procedure used. , Evidence of Compliance:
- Records of completed instrument/method verification consistent with manufacturer’s recommendations OR records of an alternative documented verification procedure approved by the section director”
CYP.05285, Instrument Downtime
There is a documented procedure for handling workload during instrument failure and/or downtime., NOTE: This procedure must address: (a) final processing and resulting of any cases/specimens that are within the instrument at the time of failure, and (b) alternative procedures to be used during instrument downtime. ,
CYP.05292, Unsuccessful Slide Processing
“The laboratory has defined a system to handle slides that are not successfully processed by the instrument., NOTE: Laboratories must clearly identify slides that fail screening by an automated instrument and ensure that these slides are completely rescreened by another method. In most instances, manual rescreening will be used. , Evidence of Compliance:
- Records of slide rescreening”
CYP.05300, Result Reporting
“The cytopathology report includes all of the following required elements.
- Name of patient and unique identifying number, if available
- Age and/or birth date of patient
- Date of collection
- Accession number
- Name of physician and/or clinic
- Name of the responsible reviewing pathologist, when applicable
- Name and address of the laboratory location where the test was performed
- Date of report
- Test performed
- Anatomic source and/or type of specimen
- Basis for correction/amendment (if applicable), NOTE: Refer to CYP.05316 below for additional details regarding the reviewing pathologist., “
CYP.05316, Pathologist Identification on Report
“The cytopathology report clearly indicates the name of the pathologist who has reviewed the slides, when applicable., NOTE: The records must indicate those who have reviewed the cytology slides. Cytotechnologists should be identifiable by name, initials, or other identifier in laboratory records. When a pathologist has performed a diagnostic review of the slides, the report must indicate his/her name or signature (in written or electronic form). The reviewing pathologist’s name must be distinct from any other pathologist names (e.g. the laboratory director) on the report. Electronic signatures must be secure and traceable to the reviewing pathologist. A report may contain the signature/initials of a pathologist or cytotechnologist attesting to an activity other than review of the slides (for example, verification of results of automated screening instruments), but in such cases the report must clearly indicate that the signature/initials attest to the other activity, not review of the slides.
When slides are reviewed by a pathologist for quality control purposes only (e.g. the 10% rescreen of gynecologic cytopathology cases), the name of the pathologist must be retained in laboratory records but need not be included on the report., “
CYP.05332, Report Review
“Cytopathology reports are reviewed and signed by the pathologist, when applicable., NOTE: For gynecologic cases reviewed by a pathologist, and for all non-gynecologic cases, the laboratory must ensure and document that the reviewing pathologist has reviewed and approved the completed report before release. In the occasional situation when the diagnosing pathologist is not available for timely review and approval of the completed report, the laboratory may have a policy and procedure for review and approval of that report by another pathologist. In that circumstance, the names and responsibilities of both the pathologist who made the diagnosis and the pathologist who performs final verification must appear on the report.
This checklist requirement does not apply to cases reviewed by a pathologist for quality control purposes only (e.g. the 10% rescreen of gynecologic cytopathology cases)., “
CYP.05350, Report Elements
“The cytopathology report includes all of the following desirable elements.
- Date specimen received/accessioned by the laboratory
- Description of specimen on receipt (e.g. bloody fluid)
- Designation of automated screening device, when applicable, NOTE: Description of specimens on receipt should document the type of specimen received. Examples include the number of glass slides submitted and how fixed (e.g. air-dried or alcohol-fixed); quantity of fluid and fixation (e.g. 10cc bloody fluid in alcohol); Thin Prep vial; SurePath vial; brush in 10cc clear yellow fluid, etc. , “
CYP.06100, Report - Morphologic Findings
“The cytopathology report includes an interpretation of the morphologic findings, and, as appropriate, standard descriptive terminology., NOTE: Cytopathology reports must clearly communicate whether disease is present, absent, or uncertain, as the case may be. When a definite diagnosis cannot be rendered (i.e. terms such as “inconclusive,” “indeterminate” or “non-diagnostic” are used), the reason should be given.
Reports must include a concise descriptive diagnosis either in a format similar to a histopathology report, or standard descriptive terminology that includes a general categorization and descriptive diagnosis (as is recommended by the Bethesda System for gynecologic cytopathology reports). The use of diagnostic ““classes”” is not recommended, as it does not reflect current understanding of neoplasia, has no comparable equivalent in diagnostic histopathologic terminology, and does not provide for diagnosis of non-neoplastic conditions.
A simple diagnosis of ““Negative”” is not an adequate descriptive diagnosis. However, a diagnosis such as, ““Negative for malignancy”” or “No malignant cells identified”” is acceptable for non-gynecologic exfoliative cytology specimens (i.e.urine, fluids, washings and brushings). When appropriate (particularly for fine needle aspiration samples of mass lesions), a statement regarding the adequacy of the specimen should be included, with a description of the limitations of the specimen when a specific diagnosis cannot be made., Evidence of Compliance:
- Written procedure defining criteria for reporting morphologic findings “
CYP.06450, Significant/Unexpected Findings
“There is a policy regarding the communication, and documentation thereof, of significant and unexpected cytopathology findings., NOTE: Certain cytopathology diagnoses may be considered particularly significant and unexpected. For example, such diagnoses may include invasive carcinoma found in a cervicovaginal specimen, malignancy in an effusion with no patient history of neoplasm etc.. There should be a reasonable effort to ensure that such diagnoses are received by the clinician, by means of telephone, pager, or other system of notification. There must be documentation of the date of these diagnoses.
Diagnoses to be defined as ““significant and unexpected,”” should be determined by the cytopathology department, in cooperation with local clinical medical staff.
This requirement takes the place of critical result notification in the All Common Checklist (COM.30000 and COM.30100)., Evidence of Compliance:
- Records of communication of significant/unexpected findings”